1. Ahre A, Bjorkholm M, Mellstedt H, et al. Human leukocyte interferon and intermittent high-dose melphalan-prednisone administration in the treatment of multiple myeloma: a randomized clinical trial from the Myeloma Group of Central Sweden. Cancer Treat Rep 1984; 68: 1331–1338.
2. Einhorn S, Ahre A, Blomgren H, Johansson B, Mellstedt H, Strander H. Interferon and natural killer activity in multiple myeloma. Lack of correlation between interferon-induced enhancement of natural killer activity and clinical response to human interferon-alpha. Int J Cancer 1982; 30: 167–172.
3. Janson CH, Tehrani M, Wigzell H, Mellstedt H. Rational use of biological response modifiers in hematological malignancies a review of treatment with interferon, cytotoxic cells and antibodies. Leuk Res 1989; 13: 1039–1046.
4. Tossing G. New developments in interferon therapy. Eur J Med Res 2001; 6: 47–65.
5. Wills RJ, Spiegel HE, Soike KF. Pharmacokinetics of recombinant alpha A interferon following I.V. infusion and bolus, I.M., and P.O. administrations to African green monkeys. J Interferon Res 1984; 4: 399–409.